NextBioMedical Co

NextBioMedical Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is -819.95. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 348.04 — a change of -335.59% (lower).

EV/EBITDA

-819.95

YoY

-335.59%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of NextBioMedical Co is 2025 -819.95 . EV/EBITDA (Enterprise Value to EBITDA) of NextBioMedical Co was 2024 348.04 . It decreases by -335.59% lower compared to the previous year.

The NextBioMedical Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2021
-84.51 KRW
Jan 1, 2022
-121.92 KRW
Jan 1, 2023
-76.83 KRW
Jan 1, 2024
348.04 KRW
Jan 1, 2025
-819.95 KRW
The NextBioMedical Co EV/EBITDA history
YEAREV/EBITDAYoY
-819.95-335.59%
348.04-553.02%
-76.83-36.99%
-121.92+44.27%
-84.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

EV/EBITDA (Enterprise Value to EBITDA) of NextBioMedical Co is -819.95 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of NextBioMedical Co changed from 348.04 to -819.95, representing a -335.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s NextBioMedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — NextBioMedical Co

All Key Metrics — NextBioMedical Co